Jannet Beukema

142 Appendices Publications 1. Suvaal I, Hummel SB, Mens JM, Tuijnman-Raasveld CC, Tsonaka R, Velema LA, Westerveld H, Cnossen JS, Snyers A, Jürgenliemk-Schulz IM, Lutgens LCHW, Beukema JC, Haverkort MAD, Nowee ME, Nout RA, de Kroon CD, van den Hout WB, Creutzberg CL, van Doorn HC, Ter Kuile MM. Efficacy of a nurse-led sexual rehabilitation intervention for women with gynaecological cancers receiving radiotherapy: results of a randomised trial. Br J Cancer. 2024 Jul 3;. doi: 10.1038/s41416-024-02775-8 2. Beukema JC, de Groot C, Plukker JTM, Vliegenthart R, Langendijk JA, van Luijk P, van Melle JP, Prakken NHJ, Muijs CT. Late cardiac toxicity of neo-adjuvant chemoradiation in esophageal cancer survivors: A prospective cross-sectional pilot study. Radiother Oncol. 2021 Dec 2;167:72-77 3. van Triest B, Rasing M, van der Velden J, de Hullu J, Witteveen PO, Beukema JC, van der Steen-Banasik E, Westerveld H, Snyers A, Peters M, Creutzberg CL, Nout RA, Lutgens L, Jürgenliemk-Schulz I. Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study. Gynecol Oncol. 2021 Oct;163(1):117-124 4. Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch OR, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Spillenaar Bilgen EJ, van der Sangen MJC, Rozema T, Ten Kate FJW, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS Study Group. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J Clin Oncol. 2021 Jun 20;39(18):1995-2004 5. Dijkstra EA, Mul VEM, Hemmer PHJ, Havenga K, Hospers GAP, Kats-Ugurlu G, Beukema JC, Berveling MJ, El Moumni M, Muijs CT, van Etten B. Clinical selection strategy for and evaluation of intra-operative brachytherapy in patients with locally advanced and recurrent rectal cancer. Radiother Oncol. 2021 Jun;159:91-97 6. Post CCB, Mens JWM, Haverkort MAD, Koppe F, Jürgenliemk-Schulz IM, Snyers A, Roeloffzen EMA, Schaake EE, Slot A, Stam TC, Beukema JC, van den Berg HA, Lutgens LCHW, Nijman HW, de Kroon CD, Kroep JR, Stiggelbout AM, Creutzberg CL. Patients’ and clinicians’ preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making. Gynecol Oncol. 2021 Jun;161(3):727-733 7. de Groot C, Beukema JC, Langendijk JA, van der Laan HP, van Luijk P, van Melle JP, Muijs CT, Prakken NHJ. Radiation-Induced Myocardial Fibrosis in Long-Term Esophageal Cancer Survivors. Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):1013-1021 8. Gort EM, Beukema JC, Matysiak W, Sijtsema NM, Aluwini S, Langendijk JA, Both S, Brouwer CL. Inter-fraction motion robustness and organ sparing potential of proton therapy for cervical cancer. Radiother Oncol. 2021 Jan;154:194-200 9. Beukema JC, Kawaguchi Y, Sijtsema NM, Zhai TT, Langendijk JA, van Dijk LV, van Luijk P, Teshima T, Muijs CT. Can we safely reduce the radiation dose to the heart while compromising the dose to the lungs in oesophageal cancer patients? Radiother Oncol. 2020 Aug;149:222-227 10. Noordman BJ, Verdam MGE, Lagarde SM, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch OR, Ten Kate FJW, Creemers GM,

RkJQdWJsaXNoZXIy MTk4NDMw